Related Experiment Video

Updated: Sep 29, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA

JinYuan He1, Jie Liu1, HongJie Shen2

  • 1Department of Hematology, Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, 213003, China.

International Journal of Hematology
|March 22, 2022
PubMed
Abstract

Insights

This study reveals distinct co-mutation patterns in Acute Myeloid Leukemia (AML) with CEBPA single (sm) or double (dm) mutations. These co-mutations impact clinical features and remission rates differently based on CEBPA mutational status.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute Myeloid Leukemia (AML) is a heterogeneous cancer with various genetic mutations influencing prognosis.
  • CCAAT enhancer binding protein alpha (CEBPA) mutations are common in AML and can occur as single (CEBPAsm) or double (CEBPAdm) mutations.
  • Understanding co-occurring mutations in CEBPA-mutated AML is crucial for predicting clinical outcomes.

Purpose of the Study:

  • To investigate the spectrum of co-mutations in a large cohort of CEBPA-mutated AML patients.
  • To analyze the clinical impact of these co-mutations on patient characteristics and treatment response.
  • To differentiate the co-mutation profiles and clinical features between CEBPAsm and CEBPAdm AML.

Main Methods:

  • Retrospective analysis of 302 patients with CEBPA-mutated AML.
  • Next-generation sequencing (NGS) of 112 genes to identify co-mutations.
  • Statistical analysis to compare mutation frequencies and clinical features between CEBPAsm and CEBPAdm groups.

Main Results:

  • CEBPAdm AML showed increased mutations in CSF3R, GATA2, and WT1.
  • CEBPAsm AML exhibited higher frequencies of NPM1, FLT3-ITD, and NOTCH2 mutations, as well as alterations in signaling pathways and spliceosomes.
  • Specific co-mutations (e.g., CEBPAsm/TET2mut, CEBPAdm/TET2mut) were associated with distinct hematological parameters (platelet count, hemoglobin levels).
  • The complete remission (CR) rate for FLT3-ITD mutations was lower in CEBPAsm than CEBPAdm AML.

Conclusions:

  • CEBPAsm and CEBPAdm AML are characterized by distinct co-mutation clusters.
  • Co-mutations significantly influence clinical features, including hematological parameters and complete remission rates.
  • The specific CEBPA mutational status (sm vs. dm) dictates the impact of co-mutations on AML patient outcomes.
Keywords:
CEBPAFLT3LeukemiaMutationsNext-generation sequencing

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.1K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Complementation Tests00:49

Complementation Tests

A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
5.4K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
5.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.2K